Clinical Data at Initial Evaluation
| . | HU . | Pi . |
|---|---|---|
| . | (150 cases) . | (142 cases) . |
| Age (mean) | M = 53.2 F = 53.6 | M = 55.1 F = 53.3 |
| Sex ratio (m/f) | 0.89 | 1.20 |
| Hematological criteria (% of cases) | ||
| Increase of 2 cell lines + splenomegaly; or increase of 3 cell lines | 70 | 68 |
| Increase of red cell line + hyperleucocytosis or thrombocytosis, without splenomegaly | 25 | 24 |
| Increase of red cell line alone + abnormal value and spontaneous growth of erythropoietin BFU/E | 5 | 8 |
| Vascular risk (% of cases) | ||
| High* | 11 | 11 |
| Moderate† | 15 | 14 |
| None | 74 | 75 |
| . | HU . | Pi . |
|---|---|---|
| . | (150 cases) . | (142 cases) . |
| Age (mean) | M = 53.2 F = 53.6 | M = 55.1 F = 53.3 |
| Sex ratio (m/f) | 0.89 | 1.20 |
| Hematological criteria (% of cases) | ||
| Increase of 2 cell lines + splenomegaly; or increase of 3 cell lines | 70 | 68 |
| Increase of red cell line + hyperleucocytosis or thrombocytosis, without splenomegaly | 25 | 24 |
| Increase of red cell line alone + abnormal value and spontaneous growth of erythropoietin BFU/E | 5 | 8 |
| Vascular risk (% of cases) | ||
| High* | 11 | 11 |
| Moderate† | 15 | 14 |
| None | 74 | 75 |